Robert A Kratzke

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide
    Blake A Jacobson
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 8:e81669. 2013
  2. pmc Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
    B A Jacobson
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Cancer 101:424-31. 2009
  3. doi request reprint Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904
    Robert A Kratzke
    Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:417-21. 2008
  4. doi request reprint Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity
    Bryan A Whitson
    Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
    Ann Thorac Surg 86:1735-44. 2008
  5. ncbi request reprint Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Lung Cancer 58:196-204. 2007
  6. doi request reprint Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system
    Brent W Williams
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55414, USA
    Cancer Lett 284:37-46. 2009
  7. doi request reprint Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer
    Arkadiusz Z Dudek
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 4:969-75. 2009
  8. pmc Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC
    Manish R Patel
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    J Thorac Oncol 8:1142-7. 2013
  9. pmc Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation
    Manish R Patel
    University of Minnesota Medical School, Division of Hematology, Oncology, and Transplantation, Minneapolis, MN 55455, USA
    Int J Oncol 40:577-82. 2012
  10. ncbi request reprint Ras pathway activation in malignant mesothelioma
    Manish R Patel
    Division of Hematology Oncology Transplant, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 2:789-95. 2007

Detail Information

Publications52

  1. pmc Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide
    Blake A Jacobson
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 8:e81669. 2013
    ..In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma...
  2. pmc Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
    B A Jacobson
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Cancer 101:424-31. 2009
    ..Studies have found that tumourigenesis is linked to dysregulation of cap-dependent protein translation...
  3. doi request reprint Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904
    Robert A Kratzke
    Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:417-21. 2008
    ..This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC)...
  4. doi request reprint Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity
    Bryan A Whitson
    Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
    Ann Thorac Surg 86:1735-44. 2008
    ..Specifically, we assessed the cytotoxic capacity of peripheral blood mononuclear cells (PBMCs) of patients undergoing lobectomy for non-small-cell lung cancer by either VATS or thoracotomy...
  5. ncbi request reprint Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Lung Cancer 58:196-204. 2007
    ..0085). In conclusion, gemcitabine infused by this novel method induced apoptosis after both the short and continuous infusions, and long-term survival was significantly diminished following continuous compared with the short infusion...
  6. doi request reprint Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system
    Brent W Williams
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55414, USA
    Cancer Lett 284:37-46. 2009
    ..We conclude that cap-dependent translation blockade and fixed dose rate infusion gemcitabine treatment results in a significant interaction affecting cell viability in vitro...
  7. doi request reprint Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer
    Arkadiusz Z Dudek
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 4:969-75. 2009
    ..A secondary goal was to assay a panel of candidate serum biomarkers before and after neoadjuvant therapy...
  8. pmc Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC
    Manish R Patel
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    J Thorac Oncol 8:1142-7. 2013
    ..Because Akt activation results in downstream initiation of cap-dependent protein translation, we hypothesized that a strategy of targeting cap-dependent translation in combination with erlotinib might enhance therapy...
  9. pmc Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation
    Manish R Patel
    University of Minnesota Medical School, Division of Hematology, Oncology, and Transplantation, Minneapolis, MN 55455, USA
    Int J Oncol 40:577-82. 2012
    ..Our data provide evidence that JNK is involved in the regulation of translation and has potential as a therapeutic target in NSCLC...
  10. ncbi request reprint Ras pathway activation in malignant mesothelioma
    Manish R Patel
    Division of Hematology Oncology Transplant, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 2:789-95. 2007
    ..Mutations in Ras family genes are rare in malignant mesothelioma. The role of activation of the Ras signaling pathway in the pathogenesis of mesothelioma is not clear...
  11. ncbi request reprint EUS-guided FNA for the diagnosis of advanced lung cancer
    Mandeep S Sawhney
    Section of Gastroenterology, Center for Epidemiological and Clinical Research, Minneapolis VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
    Gastrointest Endosc 63:959-65. 2006
    ..Currently available diagnostic methods are either too risky or unsuccessful in obtaining a tissue diagnosis in up to 30% of patients...
  12. pmc Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer
    Steven F Powell
    Division of Hematology, Oncology and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA
    Clin Lung Cancer 14:495-501. 2013
    ..This clinical trial evaluated whether topotecan in combination with bevacizumab improved progression-free survival (PFS) in patients with advanced, refractory non--small-cell lung cancer in a second-line setting...
  13. doi request reprint Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas
    Bryan A Whitson
    Department of Surgery, Division of Thoracic and Foregut Surgery, University of Minnesota, Minneapolis, MN 55455, USA
    J Thorac Cardiovasc Surg 139:43-8. 2010
    ..We hypothesized that gastroesophageal junction adenocarcinomas (eg, gastric cardia and distal esophageal tumors) were not distinct entities and had similar survival...
  14. ncbi request reprint Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award
    Bryan A Whitson
    Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Ann Thorac Surg 82:996-1001; discussion 1001-2. 2006
    ..Recent data have shown that insulin-like growth factor-1 receptor (IGF-1R) may play a role in oncogenic signaling. Our aim was to evaluate the effect of a novel IGF-1R inhibitor, NVP-AEW541, on cell growth and IGF associated pathways...
  15. doi request reprint Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells
    Bryan A Whitson
    Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Surg Obes Relat Dis 5:181-93. 2009
    ..We hypothesized that the open approach to Roux-en-Y gastric bypass (RYGB) has a more deleterious, negative, quantifiable effect on the peripheral blood mononuclear cells than does the MIS approach...
  16. ncbi request reprint Gene expression profiling identifies matriptase overexpression in malignant mesothelioma
    Chuong D Hoang
    Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota Medical School, Minneapolis, MN, USA
    Chest 125:1843-52. 2004
    ..We investigated the gene expression profiles of malignant pleural mesothelioma (MPM) specimens to identify novel genes that are potentially involved in the oncogenic transformation of human pleural cells...
  17. pmc Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report
    Arkadiusz Z Dudek
    Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA
    J Thorac Oncol 7:755-9. 2012
    ..We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment...
  18. pmc Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II
    Ahad A Sadiq
    Division of Hematology Oncology Transplant, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
    Invest New Drugs 28:20-5. 2010
    ..We tested SD8 activity alone and in combination with cisplatin against malignant mesothelioma (MM) and non-small cell cancer (NSCLC) cell lines...
  19. ncbi request reprint ERBB2 amplifications in esophageal adenocarcinoma
    Peter S Dahlberg
    Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Hennepin County Medical Center, Minneapolis, Minnesota 55455, USA
    Ann Thorac Surg 78:1790-800. 2004
    ....
  20. ncbi request reprint Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial
    Jonathan D'Cunha
    Division of Cardiovascular and Thoracic Surgery, University of Minnesota Medical School, Minneapolis, MN, USA
    Lung Cancer 48:241-6. 2005
    ..Herein, we present data from Cancer and Leukemia Group B (CALGB) protocol 9761 evaluating the correspondence between clinical and pathologic analysis in early stage NSCLC...
  21. ncbi request reprint Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer
    Bryan A Whitson
    Department of Surgery, Section of Thoracic and Foregut Surgery, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA
    Ann Thorac Surg 83:1965-70. 2007
    ..We compared the operative characteristics and postoperative course for patients with clinical stage I NSCLC who underwent lobectomy by VATS or thoracotomy...
  22. doi request reprint Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues
    Dhatri Kodali
    Hematology Oncology Section, Departments of Medicine, Veterans Administration Medical Center, Minneapolis, Minnesota, USA
    Arch Pathol Lab Med 135:365-71. 2011
    ..eIF-4F activity is controlled by a repressor binding protein (4E-BP1), which promotes translation when phosphorylated...
  23. ncbi request reprint Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, 308 Harvard St SE, Minneapolis, MN 55455, USA
    Cancer Chemother Pharmacol 61:291-9. 2008
    ..The aim of this study was to assess for gemcitabine-induced cell death following infusion of drug under clinically-relevant conditions of infusion rate and drug exposure in an in vitro bioreactor system...
  24. doi request reprint Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors
    Amit K Mitra
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Pharmacogenomics 13:1009-21. 2012
    ..The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy...
  25. ncbi request reprint Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes
    Chuong D Hoang
    Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Cancer Res 64:7479-85. 2004
    ..Thus, these data suggest that multiple mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis. Therefore, IGF system components represent novel malignant pleural mesothelioma therapeutic targets for investigation...
  26. ncbi request reprint Quantification of colorectal cancer micrometastases in lymph nodes by nested and real-time reverse transcriptase-PCR analysis for carcinoembryonic antigen
    Samuel B Ho
    Departments of Medicine, Surgery, and Laboratory Medicine, Veterans Affairs Medical Center, Minneapolis, MN, USA
    Clin Cancer Res 10:5777-84. 2004
    ..These assays are not quantitative and can be confounded by false-positive results. The purpose of this study was to determine whether quantification of CEA in lymph nodes could more readily identify clinically relevant groups...
  27. ncbi request reprint Endoscopic ultrasound and positron emission tomography for lung cancer staging
    Mandeep S Sawhney
    Section of Gastroenterology, Minneapolis VA Medical Center, Minneapolis, Minnesota 55417, USA
    Clin Gastroenterol Hepatol 4:846-51. 2006
    ..We prospectively compared 2 promising new modalities, positron emission tomography (PET) and endoscopic ultrasound (EUS), for staging mediastinal lymph nodes...
  28. ncbi request reprint Inactivation of p16INK4a expression in malignant mesothelioma by methylation
    Long Wong
    Research Service, Minneapolis VA Medical Center, Minneapolis, MN, USA
    Lung Cancer 38:131-6. 2002
    ..We are further exploring the clinical significance of inhibition of methylation in mesothelioma by cytidine analogs. This may provide a potential treatment target in some mesothelioma tumors by inhibition of methylation...
  29. ncbi request reprint Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide
    Sandra P Frizelle
    Research Service, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Anticancer Res 28:1-7. 2008
    ..This study tested the hypothesis that reexpression of p16INK4a carried out using the TAT delivery system that carries the protein transduction domain of the HIV TAT will result in mesothelioma cell death...
  30. ncbi request reprint Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives
    David M Ferguson
    Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, U S A Department of Pharmacology, University of Minnesota, Minneapolis, MN, U S A
    Anticancer Res 35:5211-7. 2015
    ..This has led to the development of acridine-based agents, which are catalytic TOPOII inhibitors, that do not generate DNA strand breaks that can lead to secondary malignancies in in vitro tests...
  31. doi request reprint Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells
    Esther Z Chen
    Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA
    Invest New Drugs 32:598-603. 2014
    ..4Ei-1 is a novel prodrug that reduces proliferation, represses colony formation, diminishes association of eIF4F with the mRNA cap, and sensitizes mesothelioma cells to pemetrexed. ..
  32. pmc Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer
    Naomi Fujioka
    Department of Medicine, Division of Hematology, Oncology, Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Anesth Analg 113:1353-64. 2011
    ..We hypothesized that clinically used opioid analgesics that are MOR agonists coactivate EGFR, resulting in growth- and survival-promoting signaling...
  33. pmc Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model
    Ranjana Mitra
    Division of Hematology, Department of Medicine, School of Public Health, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 17:2934-46. 2011
    ....
  34. ncbi request reprint Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761
    Jonathan D'Cunha
    Division of Cardiovascular and Thoracic Surgery, University of Minnesota Medical School, 420 Delaware Street, Minneapolis, MN 55455, USA
    J Thorac Cardiovasc Surg 123:484-91; discussion 491. 2002
    ..This study evaluated the ability of quantitative reverse-transcriptase polymerase chain reaction to quantitate lymph node occult metastases with carcinoembryonic antigen messenger RNA as a tumor marker...
  35. doi request reprint Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
    Manish R Patel
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Oncotarget 6:33165-77. 2015
    ..Tumor cell expression of PDL-1 was increased after VSV-IFNβ treatment. VSV-IFNβ has potent antitumor effects and promotes systemic antitumor immunity. These data support further clinical investigation of VSV-IFNβ for NSCLC. ..
  36. doi request reprint Oncolytic virus therapy for cancer: the first wave of translational clinical trials
    Manish R Patel
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minn, USA
    Transl Res 161:355-64. 2013
    ..The following review will focus on the first wave of clinical translation of oncolytic virus therapy, what has been learned so far, and potential challenges ahead for advancing the field...
  37. ncbi request reprint Molecular prognostic markers in malignant mesothelioma
    Priya Kumar
    Thoracic Oncology Program, Section of Heme Onc Transplant, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Lung Cancer 49:S53-60. 2005
    ..Alterations in cell cycle control proteins such as p16, p21, and p27 also offer information on prognosis and represent potential targets for therapy...
  38. ncbi request reprint Molecular pathways in malignant pleural mesothelioma
    Bryan A Whitson
    Division of Hematology Oncology Transplant University of Minnesota Medical School, Department of Surgery, Section of Heme Onc Transplant, 480 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Lett 239:183-9. 2006
    ..Correlations to potential therapeutic modalities are made...
  39. ncbi request reprint Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden
    Chuong D Hoang
    Division of Cardiovascular and Thoracic Surgery, University of Minnesota Medical School, Minneapolis, Minn, USA
    J Thorac Cardiovasc Surg 127:1332-41; discussion 1342. 2004
    ..This study hypothesized that non-small cell lung carcinoma cells from primary tumors isolated by laser capture microdissection would exhibit gene expression profiles associated with graded lymph node metastatic cell burden...
  40. doi request reprint p16(INK4a) Peptide mimetics identified via virtual screening
    Mark A Klein
    Research Service, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Bioorg Med Chem Lett 20:403-5. 2010
    ..Four compounds were subsequently shown to inhibit Cdk4 and/or Cdk6 with IC(50) in the muM range. These compounds form lead compounds upon which further cell cycle inhibitors can be developed...
  41. doi request reprint Lung cancer and lung transplantation: a review
    Josy Mathew
    Department of Medicine, Division of Hematology Oncology, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    J Thorac Oncol 4:753-60. 2009
    ..Attention needs to be focused on detecting lung cancer early in these patients to achieve a favorable outcome...
  42. ncbi request reprint Translational control: a target for cancer therapy
    Saritha C Thumma
    The Division of Hematology Oncology Transplant, Department of Medicine, The University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Cancer Lett 258:1-8. 2007
    ..Return of normal translational control is associated with loss of tumorigenic potential in pre-clinical models. Currently, a variety of novel therapeutics are in development targeting this mechanism as a treatment for cancer...
  43. ncbi request reprint Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer
    Arkadiusz Z Dudek
    Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, MMC 286, 420 Delaware St S E, Minneapolis, MN, 55455, USA
    Lung 183:43-52. 2005
    ..After a median follow-up of 184 days, 13 patients died (76%). Median overall survival was 164 days. The combination of gemcitabine and vinorelbine has limited activity in relapsed SCLC...
  44. ncbi request reprint Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs
    Chuong D Hoang
    Division of Cardiovascular and Thoracic Surgery, Department of Surgery, USA
    Cancer Detect Prev 29:509-17. 2005
    ..We tested this hypothesis by examining the molecular differences, if any, between primary tumor cells and matched lymph node metastatic cells in human non-small-cell lung carcinoma specimens...
  45. doi request reprint Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Division of Hematology Oncology 111H, 22 South Greene Street, Baltimore, MD 21201 1595, USA
    J Clin Oncol 26:848-55. 2008
    ....
  46. ncbi request reprint Bone morphogenetic protein 3B silencing in non-small-cell lung cancer
    Zunyan Dai
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Oncogene 23:3521-9. 2004
    ..05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms in lung cancer, and that the silencing of BMP3B promotes lung tumor development...
  47. ncbi request reprint Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, 4960 Children s Place, Suite 108, St Louis, MO 63110, USA
    Clin Cancer Res 11:2300-4. 2005
    ..The Cancer and Leukemia Group B conducted a phase II study of gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously untreated malignant mesothelioma...
  48. ncbi request reprint Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo
    Blake A Jacobson
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Cancer Res 66:4256-62. 2006
    ....
  49. ncbi request reprint Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761
    Robin T Vollmer
    Laboratory Medicine 113, VA Medical Center, Durham, North Carolina 27705, USA
    Clin Cancer Res 9:5630-5. 2003
    ..Our purpose was to study the detection of occult metastases (OM) in regional lymph nodes using immunohistochemical stain for cytokeratin, and for this study we targeted clinical stage I patients with non-small cell lung cancer...
  50. ncbi request reprint Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 66:352-61. 2006
    ..Ultimately, c-Met would be an important target for therapy against MPM...
  51. ncbi request reprint Central intranodal blood vessel: a new EUS sign described in mediastinal lymph nodes
    Mandeep S Sawhney
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Gastrointest Endosc 65:602-8. 2007
    ..The vascular architecture of normal lymph nodes is composed of prominent centrally located blood vessels. In malignant nodes, this pattern is distorted because of tumor infiltration and neovascularization...
  52. ncbi request reprint The pathogenesis of mesothelioma
    Michele Carbone
    Cancer Immunology Program, Cardinal Bernardin Cancer Center, Department of Pathology, Loyola University Chicago, USA
    Semin Oncol 29:2-17. 2002
    ..Mesothelioma appears to have a complex etiology in which environmental carcinogens (asbestos and erionite), ionizing radiation, viruses, and genetic factors act alone or in concert to cause malignancy...